1. Health technology

  2. •

    Pharmaceuticals: major
Novartis AG

Novartis AG

164.98
USD
+5.72
(+3.59%)
6.58EPS
23.66P/E
296.01BMarket Cap
Novartis AG
NYSE:NVS
(New York Stock Exchange)

Recent

price

164.98

P/E

ratio

23.66

div

yld

2.86%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
21.23
23.52
19.79
19.39
22.11
21.14
21.29
18.13
19.66
20.68
19.51
18
18.53
19.02
23.4
23.31
23.78
Revenue per Share
4.03
3.54
3.53
3.37
4.21
7.46
2.89
3.22
5.38
4.98
3.16
9.83
2.97
6.05
5.4
5.75
5.35
Basic EPS, GAAP
4.87
4.72
4.35
3.6
4.33
3.52
3.7
4.31
4.96
4.83
4.33
5.12
5.12
4.77
6.25
6.27
6.29
Free Cash Flow per Basic Share
1.85
2.13
2.3
2.24
2.81
2.79
2.79
2.71
2.97
2.82
2.73
3.02
3.2
2.96
3.45
3.22
3.82
Dividend per Share
25.98
25.82
26.3
27.51
29.51
32.71
32.28
31.36
33.63
23.83
22.33
27.79
26.03
19.32
20.36
19.28
17.77
Book Value per Share
-0.71
1.54
2.94
5.73
7.35
4.95
5.4
5.25
1.97
0.07
-4.03
1.59
-0.7
-1.47
-3.52
-3.7
-11.68
Tangible Book Value per Share
2,272
2,367
2,403
2,426
2,411
2,388
2,363
2,331
2,304
2,277
2,263
2,229
2,167
2,064
2,005
1,927
1,904
Basic Weighted Avg Shares
48,230
55,682
47,553
47,023
53,304
50,470
50,314
42,264
45,297
47,070
44,144
40,112
40,160
39,245
46,921
44,907
45,278
Sales/Revenue/Turnover
22.35
18.16
22.14
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.18
Operating Margin (%)
3,198
5,428
4,064
3,929
4,653
5,480
6,150
4,612
5,120
5,634
5,719
5,105
6,196
6,962
5,506
4,219
4,425
Depreciation Expense
9,161
8,384
8,482
8,184
10,147
17,812
6,831
7,501
12,392
11,345
7,141
21,911
6,427
12,490
10,833
11,081
10,190
Net Income, GAAP
14.81
14.05
15.18
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
17.9
Effective Tax Rate (%)
18.99
15.06
17.84
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
22.5
Profit Margin (%)
1,896
878
3,617
3,723
10,523
-864
2,770
4,679
5,852
1,199
-2,996
14,148
7,627
3,441
918
2,521
-3,552
Working Capital
13,432
12,993
12,610
10,028
13,714
16,354
18,215
22,614
22,079
21,328
24,752
22,369
20,128
16,850
20,805
23,448
31,628
LT Debt
65,262
61,839
63,376
66,429
70,408
77,249
76,221
72,277
77,323
53,717
50,131
61,865
54,910
39,321
40,030
36,884
33,885
Total Equity
10.92
9.95
10.63
10.01
10.82
7.99
7.08
6.83
7.03
7.18
8.59
9.56
7.01
10.49
17.26
17.4
16.4
Return on Invested Capital (%)
11.9
10.58
11.02
10.5
12.35
19.37
7.48
8.09
12.66
12.58
9.39
25.99
8.25
18.52
17.92
17.81
16.75
Return on Capital (%)
15.47
13.87
13.57
12.63
14.85
24.15
8.91
10.11
16.58
17.33
13.77
39.2
11.03
26.55
27.35
28.97
30.49
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,583
6,298
7,967
LT Borrowings
22,135
29,898
30,285
LT Finance Leases
1,313
1,328
1,343
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,896
1,896
1,889
Market Capitalization
207,147
231,246
239,125

Working Capital

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
24,136
21,244
22,095
Cash, Cash Equivalents & STI
9,139
5,571
6,212
Accounts Receivable, Net
7,082
7,494
7,784
Inventories
4,967
5,019
5,025
Total Current Liabilities
21,615
25,050
25,647
Payables & Accruals
7,541
4,894
5,307
ST Debt
4,583
6,298
7,967
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.9%
-4.46%
-7.86%
Free Cash Flow
4.41%
5.24%
-3.55%
Net Income, GAAP
18.74%
43.91%
2.29%
Sales/Revenue/Turnover
-0.75%
0.8%
-4.29%
Total Cash Common Dividend
-0.39%
0.56%
-10.43%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,920
11,563
11,134
12,299
46,921
2025
12,038
11,759
11,420
10,982
44,907
2026
10,798
12,078
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.19
1.44
1.35
1.29
5.4
2025
1.63
1.65
1.62
1
5.75
2026
1.33
1.39
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.31
1.07
- -
- -
3.45
2025
2.41
1.02
- -
- -
3.22
2026
2.61
1.23
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Novo Nordisk A/S (NYSE:NVO)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • fool.com

    Novartis: 3 Key Takeaways for Long-Term Investors

  • zacks.com

    3 Stocks to Watch Following Guidance Upgrades

  • prnewswire.com

    BioArctic collaborator Novartis terminates agreement

  • marketwatch.com

    6 dividend stocks for investors who want to cut their exposure to the S&P 500

  • reuters.com

    Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

  • cnbc.com

    Companies promised AI gains— here's how the payoff showed up in earnings

  • seekingalpha.com

    Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach

  • zacks.com

    All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

  • zacks.com

    Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

  • cnbc.com

    A pharma giant is moving past one patent cliff — but another is already looming

  • seekingalpha.com

    Novartis AG (NVS) Q3 2026 Earnings Call Transcript

  • zacks.com

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  • marketbeat.com

    What Novartis (NVS) Said on Its Q3 Earnings Call

  • zacks.com

    4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential

  • zacks.com

    NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

  • benzinga.com

    Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

  • zacks.com

    Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

  • investors.com

    Novartis Hikes Income Forecast, But There Were Caveats Within Its Report

  • wsj.com

    Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

  • defenseworld.net

    Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity